The Relative Strength (RS) Rating for Liquidia entered a higher percentile Friday, as it got a lift from 63 to 74.
Can You Really Time The Stock Market?
This exclusive rating from Investor's Business Daily tracks market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price performance over the trailing 52 weeks stacks up against all the other stocks in our database.
History shows that the best-performing stocks tend to have an RS Rating north of 80 as they launch their largest climbs. See if Liquidia can continue to show renewed price strength and hit that benchmark.
While Liquidia is not near an ideal buy zone right now, see if it manages to form and break out from a proper chart pattern.
Liquidia posted 0% EPS growth in the latest quarterly report. Sales gains came in at 5%. The next quarterly results are expected on or around Aug. 7.
The company earns the No. 308 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, TG Therapeutics and Inhibrx Biosciences are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
